NEW YORK (GenomeWeb News) — Expression Pathology has formed an alliance with the Austrian company Oridis Biomed to offer proteomic tissue-analysis services for protein biomarker research, the companies said today.
Under the agreement, both companies will be able to offer the collaborative research services to clients in the drug-development, medical-diagnostic, and academic spheres.
The collaboration will use Expression Pathology’s Liquid Tissue and Director mass spectrometry and proteomics technologies, along with Oridis’ Tissomics high-throughput platform, and its access to formalin-fixed tissue samples.
Expression Pathology CEO Casey Eitner said the alliance will help drug and diagnostic developers to identify and measure protein biomarkers that relate to specific disease progression, drug response, and toxicity.
Oridis CEO Peter Hecht said the collaboration will allow companies to use mass spec and other pathology techniques to “mine tissue archives with detailed clinical outcomes and pathology data."